Scientists Develop New Method to Deliver Genetic Therapies Directly to Insulin-Producing Cells

Gene therapy holds promise for treating Type 1 diabetes, but scientists face a fundamental problem: how do you deliver genetic instructions to pancreatic beta cells specifically, without affecting other tissues? Lipid nanoparticles (LNPs)—the fatty spheres that carried mRNA in COVID-19 vaccines—are excellent at protecting and transporting genetic material. However, they were originally designed to reach the liver, not the pancreas.

Researchers at multiple institutions set out to redesign these nanoparticles from the ground up to target beta cells with precision. The goal was not just to deliver a therapeutic gene, but to do so efficiently and selectively.

The team used two complementary approaches. First, they screened hundreds of different chemical compositions for the nanoparticles to find formulations that naturally worked better with pancreatic beta cells. In laboratory tests, their optimized formulations achieved a 148-fold increase in how well beta cells took up the genetic cargo compared to the original Moderna LNP design.

Second, they added targeting molecules to the surface of the nanoparticles—like adding an address label to a package. For mouse studies, they attached an antibody that recognizes ZnT8, a protein abundant on beta cell surfaces. For human cells, they used a smaller antibody fragment (nanobody) targeting DPP6, another beta cell marker. These surface decorations further boosted targeting efficiency, achieving over 70% transfection in mouse pancreatic tissue.

In experiments with human beta cells grown in dishes, the dual-targeted nanoparticles successfully delivered genetic instructions (STAT2-targeted RNA) that reduced a key inflammatory protein. The treated cells showed increased expression of PDL1, a molecule associated with immune protection.

These results demonstrate proof of concept: the engineered nanoparticles can reach human beta cells and deliver functional genetic payloads. However, this is early-stage laboratory research. The work does not test whether this approach could prevent or reverse Type 1 diabetes in living organisms, nor does it evaluate safety in humans.

Many potential Type 1 diabetes therapies—including those aiming to reprogram immune cells or protect beta cells—require precise delivery to pancreatic tissue. Current approaches often lack this specificity, which limits their effectiveness and raises safety concerns.

This work solves a critical technical problem. By combining chemical design with biological targeting, the researchers have created a platform that could eventually deliver many different therapeutic payloads to beta cells. Future studies will need to test whether such approaches can prevent beta cell destruction or restore function in animal models and, eventually, people with Type 1 diabetes.

Source: ACS nano. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.